NurExone Biologic Inc. (NRXBF) news focuses on its progress as a preclinical biotechnology company developing regenerative exosome-based therapies for central nervous system injuries. The company’s updates highlight advances in its lead candidate ExoPTEN, exosome manufacturing capabilities, regulatory milestones, intellectual property, and financing activities that support its development plans.
Readers following NurExone’s news can see detailed reports on preclinical data, including dose-dependent recovery of visual function in glaucoma and optic nerve injury models and motor recovery in acute spinal cord injury models. The company also publishes laboratory analyses showing anti-inflammatory activity of its exosomes and higher biological activity compared with commercially available exosome products, which it presents as strengthening the rationale for its platform.
News releases also cover regulatory and scientific visibility, such as Orphan Drug Designation for ExoPTEN in acute spinal cord injury and invited presentations at international conferences on exosomes, regenerative medicine, and bioprocessing. These items provide insight into how NurExone is engaging with regulators and the scientific community around exosome-based therapeutics.
On the corporate side, NurExone reports on patent developments, including a U.S. Notice of Allowance and an Israeli patent grant for its exosome manufacturing process, as well as its participation in programs like ARMI’s BioFab Startup Lab. Investors can also track capital raises, warrant exercises, and private placements that fund R&D, manufacturing initiatives, and U.S. expansion through its subsidiary Exo-Top Inc., including plans for a commercial exosome production facility in Indianapolis, Indiana.
For anyone monitoring NRXBF, this news stream offers a consolidated view of scientific results, manufacturing readiness, regulatory positioning, and financial developments that shape NurExone’s trajectory in exosome-based CNS therapies.
NurExone Biologic reported its Q3 2024 financial results with a net loss of US$1.25 million, compared to US$1.16 million in Q3 2023. R&D expenses increased to US$0.50 million from US$0.40 million year-over-year, while G&A expenses rose slightly to US$0.78 million. The company's cash position strengthened to US$2.52 million as of September 30, 2024, up from US$0.54 million at end-2023, primarily due to private placements and warrant exercises generating approximately US$5.98 million. The company received European Medicines Agency's Orphan Medicinal Product Designation for its ExoPTEN therapy for acute spinal cord injury treatment.
NurExone Biologic has received Orphan Medicinal Product Designation from the European Medicines Agency (EMA) for its ExoPTEN therapy, designed to treat acute spinal cord injury. This designation provides significant benefits, including 10 years of market exclusivity upon approval, access to grants, and reduced costs for scientific advice. The therapy targets approximately 20,000 new cases of acute spinal cord injury annually in the European Union. ExoPTEN uses mesenchymal stem cell-derived extracellular vesicles loaded with siRNA targeting PTEN protein to promote nerve regeneration and functional recovery. This designation follows a similar recognition from the FDA, strengthening NurExone's global market position.
NurExone Biologic has completed the final tranche of its non-brokered private placement, raising $127,499.90 through the issuance of 231,818 Units at $0.55 per Unit. The total offering raised aggregate proceeds of $1,737,647.45 through 3,159,359 Units. Each Unit includes one Common Share and a Warrant exercisable at $0.70 for 36 months. The company will use proceeds for working capital and general corporate purposes. Additionally, NurExone has retained Independent Trading Group and Oak Hill Financial for market-making and advisory services at monthly fees of $5,000 and $10,000 respectively.
NurExone Biologic has been invited to present at two major exosome science conferences in the United States this November. The company will participate in the American Academy for Extracellular Vesicles (AAEV) Conference in Houston from November 10-13 and the ISEV TECH Conference in Baltimore from November 21-23. These invitations highlight NurExone's growing influence in developing exosome-based therapies for spinal cord injuries and optic nerve damage. The conferences provide opportunities to showcase developments, connect with industry leaders, and establish a U.S. presence before entering clinical trials.
NurExone Biologic announced a non-brokered private placement of up to $2M, with a first tranche closing for $1.61M. The offering includes 3,636,363 units at $0.55 per unit, each comprising one common share and one purchase warrant. Warrants allow the purchase of one common share at $0.70 for 36 months, subject to acceleration if the average share price exceeds $1.05 for 10 consecutive trading days. Proceeds will be used for working capital. The offering may be a related party transaction but is expected to be exempt from certain formal requirements. All securities issued are subject to a statutory hold period of four months and one day.
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) is set to participate in several prestigious conferences in October 2024, showcasing its advancements in exosome-based therapies for regenerative medicine. The company will sponsor and present at the World Orphan Drug Congress in Barcelona, highlighting its work on neuron regeneration for acute spinal cord injuries. Dr. Noa Avni will present at the Precision EV Forum 2024 in Cambridge, addressing translational challenges for therapeutic EVs. NurExone will also chair a session on GMP-compliant EV production.
Additionally, the company will present at the Israeli Society of Gene and Cell Therapy's meeting and the Bioprocess International Conference in Boston, where CEO Dr. Lior Shaltiel will discuss their ExoPTEN nanodrug for acute spinal cord injuries and other CNS conditions. These engagements aim to advance therapeutic exosomes and explore potential collaborations in the field.
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced promising results from a preclinical study of ExoPTEN for spinal cord injuries. The study demonstrated that ExoPTEN can effectively target and accumulate at injury sites up to one week after the injury occurred, potentially broadening the range of treatable patients and extending the window for effective treatment.
Key findings include:
- ExoPTEN showed strong homing capacity to injury sites even 7 days post-injury
- Later administration times resulted in higher levels of accumulation
- The highest accumulation was observed in subjects treated 7 days post-injury
- Results suggest a broad therapeutic window for intervention
These findings could significantly impact clinical trial design and patient care, offering hope for more flexible treatment regimens in spinal cord injury cases.
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has been invited to present at two prestigious conferences in September, showcasing its prominence in regenerative medicine and exosome technology. CEO Dr. Lior Shaltiel will speak at the Bioprocess International Conference in Boston from September 23-26, focusing on the company's ExoPTEN nanodrug for acute spinal cord injuries and other central nervous system indications.
Dr. Shaltiel will also participate as a panelist at the Pioneering Israel Medicine Conference in New York on September 22, sharing insights into NurExone's groundbreaking work in exosomes for regenerative medicine. These invitations highlight NurExone's growing influence in the field and provide opportunities to engage with industry leaders, researchers, and potential collaboration partners.
NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced significant advancements in their exosome manufacturing process, important for their ExoPTEN product development. The company demonstrated consistent exosome production from multiple biological sources, comparing exosomes from bone marrow-derived mesenchymal stem cells (MSCs) of different donors. Despite natural variability in starting materials, the exosomes showed consistent yields and similar size distribution.
NurExone also tested the effectiveness of exosomes in an animal model of spinal cord injury, demonstrating excellent and comparable homing abilities to the injured area. The company compared exosomes produced using 2D and 3D culture methods, finding similar homing and targeting capabilities. This advancement supports NurExone's ability to scale up production for potential commercial applications in regenerative medicine treatments.
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has announced new data for its ExoPTEN nanodrug, demonstrating significant progress towards commercial-grade manufacturing. The study focused on ExoPTEN's ability to target inflammation and injury sites when loaded with small interfering RNA (siRNA) produced by a new GMP-compliant manufacturer.
Key findings include:
- ExoPTEN showed exceptional homing capacity to injured spinal cord tissue in rats
- High concentration of the drug was observed in damaged tissue
- Results validate the quality of siRNA from the new GMP Partner
- Confirms NurExone's exosomes as an effective drug delivery system
This advancement marks a important step towards meeting quality and regulatory standards for commercial manufacturing, as the company progresses towards clinical trials.